RP
ABBV icon

Rowlandmiller & Partners’s AbbVie ABBV Stock Holding History

Rowlandmiller & Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
43,246
+180
+0.4% +$38.7K 1.98% 14
2026
Q1 		$9.37M Sell
43,066
-1,367
-3% -$303K 1.9% 17
2025
Q4 		$10.2M Sell
44,433
-431
-1% -$98.2K 1.96% 15
2025
Q3 		$10.4M Sell
44,864
-636
-1% -$130K 2.04% 13
2025
Q2 		$8.45M Sell
45,500
-64
-0.1% -$11.9K 1.74% 15
2025
Q1 		$9.55M Sell
45,564
-1,695
-4% -$330K 2.01% 15
2024
Q4 		$8.4M Buy
47,259
+35
+0.1% +$6.43K 1.76% 16
2024
Q3 		$9.33M Buy
47,224
+535
+1% +$99.8K 1.89% 15
2024
Q2 		$8.01M Sell
46,689
-90
-0.2% -$14.9K 1.75% 15
2024
Q1 		$8.52M Sell
46,779
-250
-0.5% -$43.1K 1.8% 17
2023
Q4 		$7.29M Sell
47,029
-288
-0.6% -$42K 1.67% 18
2023
Q3 		$7.05M Sell
47,317
-233
-0.5% -$34.2K 1.74% 18
2023
Q2 		$6.41M Sell
47,550
-404
-0.8% -$59.2K 1.51% 21
2023
Q1 		$7.64M Buy
47,954
+356
+0.7% +$54.4K 1.86% 16
2022
Q4 		$7.73M Sell
47,598
-320
-0.7% -$49.1K 1.91% 18
2022
Q3 		$6.43M Buy
47,918
+641
+1% +$92K 1.73% 21
2022
Q2 		$7.24M Sell
47,277
-170
-0.4% -$26K 1.85% 19
2022
Q1 		$7.69M Sell
47,447
-8,529
-15% -$1.24M 1.79% 18
2021
Q4 		$6.48M Buy
55,976
+54,533
+3,779% +$6.44M 1.45% 22
2021
Q3 		$142K Sell
1,443
-40,710
-97% -$4.65M 0.05% 134
2021
Q2 		$4.75M Buy
42,153
+2,620
+7% +$295K 1.17% 29
2021
Q1 		$4.28M Buy
39,533
+38,090
+2,640% +$4.07M 1.12% 29
2020
Q4 		$155K Sell
1,443
-62
-4% -$5.96K 0.04% 145
2020
Q3 		$115K Buy
1,505
+62
+4% +$5.84K 0.05% 140
2020
Q2 		$142K Sell
1,443
-62
-4% -$5.46K 0.05% 134
2020
Q1 		$115K Buy
1,505
+100
+7% +$8.52K 0.05% 140
2019
Q4 		$124K Buy
+1,405
New +$117K 0.04% 140

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Rowlandmiller & Partners's ABBV Position: Q2 2026 in Review

Rowlandmiller & Partners increased its AbbVie (ABBV) stake by 0.42% in Q2 2026, buying an estimated $38.7K and bringing the position to 43,246 shares worth $10.9M. The position accounts for 1.98% of the portfolio, ranked #14.

Rowlandmiller & Partners first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Rowlandmiller & Partners held 43,246 shares of AbbVie worth $10.9M as of Q2 2026.
  • Rowlandmiller & Partners bought 180 AbbVie shares in Q2 2026, an estimated $38.7K.
  • AbbVie made up 1.98% of Rowlandmiller & Partners's portfolio in Q2 2026, its #14 holding.
  • Rowlandmiller & Partners first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.